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Abstract
Monoclonal antibody (McAb) is the key tool for cancer immunodiagnosis and immunotherapy. McAb-based
immunotherapy that targets tumor antigens has had great achivement. In this study, a cell clone which kept secreting
high-titer IgG1-type McAb named NJ001 against human non-small cell lung cancer (NSCLC) cells was obtained. The titer of
purified NJ001 was 2610
6. The antigen named SP70 of NSCLC specifically identified by NJ001 was proved to be a protein
with the relative molecular mass (Mr) of 70 kDa. The results of immunohistochemical staining indicated that NJ001 could
positively react to NSCLC, but weak positively or negatively react to human small-cell lung cancer (SCLC), pulmonary
pseudotumor and other epithelial tumors. In soft agar assay, the colony formation efficiency in NJ001 groups decreased in a
dose-dependent manner. For the concentration of 100 mg/ml, 200 mg/ml and 400 mg/ml, the inhibition ratio of colony
formation was 23.4%, 62.5% and 100% respectively. Meanwhile, NJ001 caused significant reduction in tumor volume and
tumor weight compared to control mice in lung cancer xenograft model. The tumor growth inhibition ratio in 200 mg,
400 mg and 800 mg NJ001 groups was 10.44%, 37.29% and 44.04%, respectively. NJ001 also led to cytomorphological
changes and induced the apoptosis of human lung adenocarcinoma cell line SPC-A1 significantly. The newly developed
NJ001 selectively reacted to NSCLC and exhibited anti-tumor activity both in vitro and in vivo. NJ001 is of great value
concerning immunodiagnostics and immunotherapy for NSCLC and holds promise for further research regarding the
mechanism underlying tumor progression of NSCLC.
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Introduction
Lung cancer is one of the most prevalent cancers and is the
leading cause of cancer death due to the lack of a validated or
effective screening approach for early detection. This public health
burden is evident worldwide with 1.5 million lung cancer related
deaths in 2010 [1]. Non-small cell lung cancer (NSCLC) accounts
for more than 85% of lung cancer and most patients with NSCLC
have advanced disease at diagnosis. The five-year survival rate for
breast, colon, and prostate cancer, in which screening tests are
available, is four to six times longer than lung cancer. The high
morbidity/mortality and failure to achieve an early diagnosis
result in the dismal prognosis [2,3].
The therapies for lung cancer are primarily based on
traditional modes such as surgical resection, chemotherapy,
and radiotherapy; however, the curative effect obtained is less
than satisfactory [4–6]. Recently, immunotherapy for cancer has
become a method utilized as a follow-up to traditional therapy.
Antibodies are becoming a major drug modality due to their
high specificity and affinity to targets. Over two dozen
therapeutic monoclonal antibodies (McAbs) are currently
approved for the treatment of cancer and other human diseases
[7–9]. Identification of novel antigens will further improve
tumor immunotherapy. Antibody-based immunotherapy that
targets tumor antigens or cell surface markers has achieved some
success as a cancer therapy, including in NSCLC, with agents
such as cetuximab, panitumumab, matuzumab, and trastuzu-
mab [10–14].
In the present study, we produced a monoclonal antibody
designated NJ001, generated by immunizing mice with human
SPC-A1 lung adencarcinoma live cell antigen. The anti-tumor
activity of McAb NJ001 was exhibited both in vitro and in vivo.
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33009Results
Production and Characterization of NJ001
Upon immunizing BALB/c mice with human lung adenocar-
cinoma cells, 3 positive monoclonal hybridoma cell lines (NM001,
NM004, NM005) were confirmed by repeated indirect cell ELISA
testing to continuously produce antibodies and were thus selected
for expansion and recloning. Chromosome numbers of each
hybridoma karyotype were more than 95. Figure 1A was the
karyotype of NM001 hybridoma cell. Purified McAbs from ascites
were acquired by Protein A affinity purification. The McAb from
NM001 had the highest titer among the three antibodies, reaching
2610
6. NM001 and NM004 kept secreting IgG1, k- type McAb,
while NM005 secreted IgG2b, k- type McAb.
Each McAb was characterized by the results of binding to a
panel of normal and malignant cells listed in Figure 1B. By ELISA
analysis, we determined that McAbs produced by the hybridoma
cell lines NM001, NM004 and NM005 exhibited higher binding
ratios with the NSCLC cell lines SPC-A1, A549, NCI-520 and
NCI-H460, but exhibited generally lower binding ratios in SCLC
cell line NCI-H446, other cancer and normal cell lines. NJ001,
produced by the hybridoma cell line NM001, was selected for
further study because it exhibited the highest specificity for the
lung cancer cell lines compared to other tumor cell lines.
Western blot analysis results were consistent (Figure 1C). We
could only detect the expression of the protein named SP70
specific to NJ001 in NSCLC cell lines, but not in other cancer cell
lines and normal cells.
Indirect immunofluorescence results were shown in Figure 1D.
SP70, recognized by NJ001, was localized in the cell memberane
and cellular cytoplasm of SPC-A1 cells, whereas the other cell lines
exhibited no fluorescence.
Immunohistochemical Analysis
Immunohistochemical analysis results showed that the expres-
sion of the SP70 was strong positive in lung adenocarcinoma tissue
and squamous lung cancer tissue (Figure 2A, 2B), while weak
positive or negative expression was observed in the tissue of SCLC,
breast carcinoma, gastric cancer, colon cancer, ovarian cancer and
liver cancer (Figure 2C, 2D, 2E, 2F, 2G, 2H). SP70 was not found
in the tissues of pulmonary pseudotumor and adjacent non-
tumourous lung tissues (Figure 2I, 2J).
SP70 expressions in the tissue of lung adenocarcinoma,
squamous lung cancer, SCLC, breast carcinoma, gastric cancer,
colon cancer, ovarian cancer, liver cancer, pulmonary pseudotu-
mor and adjacent nontumourous lung were 58/58, 48/48, 2/21,
3/21, 1/5, 0/5, 0/5, 1/5, 0/25 and 0/8 respectively (Table 1).
Inhibitory Effects of NJ001 on SPC-A1 Proliferation and
Colony Formation
The effect of NJ001 on the proliferation of SPC-A1 cells was
evaluated via a [
3H] thymidine proliferation assay. Compared
with the control treated cells, the proliferation level of NJ001
treated SPC-A1 cells significantly decreased after 48 h and 72 h
(P,0.001, P,0.001) (Figure 3).
SPC-A1 cells were plated on a soft agar matrix, treated with
NJ001 or MCA2849 (irrelevant McAb) (0, 100, 200, 400, 800, or
1000 mg/mL) and incubated at the condition of 37uC with 5%
CO2. After 14 days, the number of colonies was counted and the
representative images were obtained (Figure 4). As shown in
Table 2, NJ001 inhibited colony formation in a dose-dependent
manner, exhibiting 23.4% inhibition ratio at 100 mg/mL, 62.5%
inhibition ratio at 200 mg/mL. When the concentration reached
400 mg/mL or higher, there were no colonies larger than 50 cells,
showing a 100% inhibition ratio. However, MCA2849 didn’t
inhibit the colony formation of SPC-A1.
These results suggested that NJ001 effectively inhibited SPC-A1
cell proliferation in vitro.
Inhibitory Effects of NJ001 in the Human SPC-A1 Lung
Adenocarcinoma Mouse Xenograft Model
In the preliminary study, after 3 weeks of inoculation, the mice
were euthanized. The tissues from the injection site in the
incubation group and the tumors in the control group were
excised. Histopathology showed no tumor growth in tissues of the
incubation group and tumor growth in tissues of the control group
(Figure 5).
The result of in vivo experiment was shown in Figure 6A. The
administration of NJ001 caused varying degrees of reduction in
tumor volume compared with the saline-treated control mice. The
tumor volumes in the 400 mg and 800 mg NJ001 group were
significantly smaller compared to the control group 17 days after
inoculation; moreover, the difference persisted to the end of the
treatment (P=0.004, P=0.003). After 3 weeks of treatment,
tumors were excised and weighed. In 200 mg, 400 mg and 800 mg
NJ001 groups, tumor growth inhibition ratio [(C-T)/C%] was
10.44%, 37.29%, and 44.04%, respectively. The inhibition ratio in
400 mg and 800 mg NJ001 group was statistically significant
compared to the control group (Figure 6B, P=0.032, P=0.015).
At the end of 3 weeks, the average tumor weight in the 200 mg and
800 mg NJ001 group was (1.5160.20) g and (0.9460.19) g, and
the difference between the two treatments was also statistically
significant (P=0.048).
Apoptosis of SPC-A1 Cells Induced by NJ001
As shown in Figure 7A, SPC-A1 cells in the NJ001 group
exhibited a marginalized and condensed chromatin matrix, as well
as shrinkage and blebbing of the cytoplasm and fragmented nuclei,
which are typical features of apoptosis. In contrast, cells in either
MCA2849 group or McAb free group maintained a normal
morphology and retained an adequate ability to proliferate.
Compared to MCA2849 group and McAb free group, the high
percentages of Annexin V
+ cells (total apoptotic rate) in NJ001
group were observed at the time point of 24 h and 48 h (P,0.001
for both time points). The difference of total apoptotic rate in
NJ001 group between 24 h time point and 48 h time point was
also statistically significant (P=0.002, Figure 7B).
As shown in Figure 7C, the percentages of Annexin V
+/PI
+ cells
(late apoptotic rate) in NJ001 group, MCA2849 group and McAb
free group were 30.89%, 2.80% and 3.58% at 24 h time point
respectively. The late apoptotic rate in NJ001 group was also
higher than the other two groups at 48 h time point (P,0.001,
P,0.001). Moreover, the late apoptotic rate in NJ001 group
significantly increased after 24 h (from 24 h to 48 h time point)
(P,0.001).
NJ001 induced the apoptosis of SPC-A1 cells in a time–
dependant manner.
Discussion
Hybridoma technology is an available tool that potentially can
produce anti-tumor antibodies and identify novel tumor antigens.
In the past several years, considerable progress has been made in
the identification of tumor-associated antigens recognized by
McAbs or autoantibodies from patients. Currently, over 1,000
tumor-associated antigens have been reported [15–20].
In the present study, 3 McAbs were produced from 3 positive
monoclonal hybridoma cell lines (NM001, NM004, NM005) that
McAb NJ001 against NSCLC and Its Characteristics
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33009Figure 1. Production and characterization of NJ001. (A) Karyotype of NM001 hybridoma cell line (6400). (B) Binding activity of McAbs to
human maligant and nonmaligant cells in culture. Undiluted supernatants from hybridomas NM001, NM004, NM005 were tested in triplicate with
indirect cell ELISA as described in ‘‘Materials and Methods’’. Each number represents the average absorbance of the substrate end product at 450 nm.
Controls without McAbs exhibited an average absorbance of 0.02. NM001 was selected for further study as it exhibited the greatest binding ratio with
lung tumor cells and the greatest specificity for the lung cancer cell lines compared with the other tumor cell lines. (C) Western blot analysis for the
McAb NJ001 against NSCLC and Its Characteristics
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the other cancer cell lines. McAb NJ001 was selected for further
study as it exhibited the highest binding ratio with lung cancer cells
and also exhibited the greatest specificity for the lung cancer cell
lines as compared with the other cancer cell lines. The results of
immunohistochemical staining indicated that NJ001 could posi-
tively react to NSCLC, but weak positively or negatively react to
human small-cell lung cancer (SCLC), pulmonary pseudotumor
and other epithelial tumors.
In addition to the high affinity and specificity, NJ001 also
exhibited anti-tumor activity both in vitro and in vivo. We observed
the effect of NJ001 on the proliferation of lung adenocarcinoma
cell line SPC-A1. Results of soft agar assay showed that the
colony formation efficiency in NJ001 groups reduced in a dose-
dependent manner. The xenograft was established by subcuta-
neous injection of SPC-A1 cells and NJ001 was administered
intraperitoneally at 3 different doses. NJ001 caused varying
degrees of decrease in tumor volume and tumor weight compared
with control mice. Moreover, when we injected the same amount
of SPC-A1 cells cultured with NJ001 for 2 h in the same way,
there was no tumor growth in nude mice. We also found that
NJ001 induced the cytomorphological changes and significantly
induced the apoptosis of SPC-A1 cells in a time-dependent mode.
This suggested that the cell apoptosis induced by NJ001 is
potentially the mechanism of the anti-tumor activity. Induction of
apoptosis is mediated either through death receptors (an extrinsic
pathway), or at the mitochondrial level (an intrinsic pathway)
[21–23]. Further identification of the apoptotic signaling
pathways in SPC-A1 cells treated with NJ001 would be helpful
in elucidating the mechanisms by which NJ001 cause anti-tumor
activity both in vitro and in vivo. Whereas, functional assays in our
study were performed only on SPC-A1 cells used to generate
NJ001. In the next study, we will do more work to observe the
growth inhibitory effects of NJ001 extended beyond a single cell
line and make it clear whether the biologic activity is specific to
the cell line tested or represents a more generalized NSCLC
response.
The importance of tumor antigens lies in their diagnostic and
potential therapeutic utility [24–33]. Additionally, tumor antigens
can also provide prognostic information for the cancer patients
[34]. The tumor-associated antigens of human lung cancer have
been recognized for many years; however, few reports have
reaction of NJ001 produced from hybridoma NM001 with different cells (human maligant and nonmaligant cells) in culture. (Lane 1, SPC-A1; lane 2,
A549; lane 3, NCI-H520; lane 4, NCI-H460; lane 5, HepG2; lane 6, ZR-75-30; lane 7, COLO 205; lane 8, WI-38; lane 9, PBMC; lane 10, Marker). GAPDH was
used as a loading control. Results indicated that the expression of protein was specific to antibody NJ001 in non-small cell lung cancer cell lines, not
in other cancer cell lines and normal cells. (D) Representative positive and negative results obtained from IIF analysis of reaction of NJ001 with
different cells observed by fluorescence and confocal microscopy analysis (6400). (a, SPC-A1; b, ZR-75-30; c, HepG2; d, WI-38). Presence of NJ001 can
be visualized in cellular cytoplasm of SPC-A1 cells, but other cell lines showed no fluorescence. Localization of the antigen specific to NJ001 may be in
cellular cytoplasm of SPC-A1 cells.
doi:10.1371/journal.pone.0033009.g001
Figure 2. Photomicrographs of immunohistochemistry staining with NJ001 (6200). Representative areas of tumor sections from (A) NSCLC
lung adenocarcinoma; (B) NSCLC squamous lung cancer; (C) SCLC; (D) Breast carcinoma; (E) Gastric cancer; (F) Colon cancer; (G) Ovarian cancer; (H)
Liver cancer; (I) Pulmonary pseudotumor; (J) Adjacent nontumourous lung tissues.
doi:10.1371/journal.pone.0033009.g002
McAb NJ001 against NSCLC and Its Characteristics
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cancer [35,36]. In this study, the antigen which was finally named
SP70 recognized by NJ001 was proven to be a protein with a
Mr of 70 kDa. Visualization of NJ001 binding by indirect
immunofluorescence indicated that SP70 was located in cytoplasm
of SPC-A1. SP70 is a potential biomarker and therapeutic target
for the immunotherapy of NSCLC.
In order to explore the function of NJ001 and the
corresponding Ag, more work is needed to evaluate the clinical
applicability. Furthermore, the marriage of target identification
with antibody enhancement technologies will ultimately be
translated into new and improved therapies for cancer patients,
thus providing further support as to the importance of the
continued study of NJ001 [7,37–39].
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The protocol was
approved by the Committee on the Ethics of Animal Experiment
of the First Affiliated Hospital of Nanjing Medical University
(Permit Number: 19A5-2373). All efforts were made to minimize
suffering.
Mononuclear cells (PBMC) from heparinized peripheral blood
were recovered from healthy adult donors of the first affiliated
hospital of Nanjing Medical University. For immunohistochemis-
try assay, NSCLC tissues (n=106), SCLC tissues (n=21), breast
carcinoma tissues (n=21), gastric cancer tissues (n=5), colon
cancer tissues (n=5), ovarian cancer tissues (n=5), liver cancer
tissues (n=5), pulmonary pseudotumor tissues (n=25) and
adjacent nontumourous lung tissues (n=8) were obtained from
the department of pathology in the same hospital between July
2009 and June 2010.
This study was approved by the Committee on the Ethics of
Treatment of Human Subjects of the First Affiliated Hospital of
Nanjing Medical University, and a written informed consent was
also obtained from each participant.
Cells and Cell Lines
Ten different human cell lines or cultures (listed in Figure 1B)
representing various normal and neoplastic tissues were used to
characterize the antibodies in this study. All of the cell lines were
purchased from cell bank of the Chinese Academy of Sciences in
Shanghai. Human lung cancer cell lines SPC-A1, NCI-H520,
NCI-H460, and NCI-H446, colon carcinoma cell line COLO
205 and normal fetal lung cell line WI-38 were grown in
RPMI1640 medium supplemented with 10% (v/v) fetal bovine
serum (FBS) (Gibco Invitrogen, Carlsbad, CA). Human lung
cancer cell lines A549, breast carcinoma cell line ZR-75-30,
liver carcinoma cell line HepG2 were cultured in RPMI1640
Table 1. Analysis the reactivity of NJ001 in different tissues by immunohistochemistry staining.
Pathological types Number of samples
Number of samples positive
reaction to NJ001 Integrated value
NSCLC (Lung adenocarcinoma) 58 58 +++
NSCLC (Squamous lung cancer) 48 48 ++,+++
SCLC 21 2 +
Breast carcinoma 21 3 +
Gastric Cancer 5 1 +
Colon Cancer 5 0 2
Ovarian cancer 5 0 2
Liver Cancer 5 1 +
Pulmonary pseudotumor 25 0 2
Adjacent nontumourous lung tissue 8 0 2
SP70 was scored by multiplication of the percentage of positive tumor cells and staining intensity according to other studies. Initially, the percentage of positive cells
was scored as: 1(,1/3), 2(1/3–2/3), and 3(.2/3). Thereafter, intensity of staining was graded as follows: 0=not detected, 1=weak, 2=moderate and 3=strong. The final
integrated value of frequency and intensity was derived with the formula: Integrated value=A6B, A and B are scores of percentage of positive cells and intensity of
staining respectively, according to the criteria mentioned above. Results were recorded as: 2(A6B=0), +(A6B=1–2), ++(A6B=3–4), +++(A6B=6–9). All the
immunohistochemistry results were assessed by 3 independent investigators who were blinded to clinical data. When a discrepancy was found, a consensus was
reached using simultaneous examination by all the 3 investigators.
doi:10.1371/journal.pone.0033009.t001
Figure 3. Inhibitory effect of NJ001 on SPC-A1 cell prolifera-
tion. Compared with the control treated cells, the level of proliferation
of NJ001 treated SPC-A1 cells significantly decreased after 48 h and
72 h (** P,0.001).
doi:10.1371/journal.pone.0033009.g003
McAb NJ001 against NSCLC and Its Characteristics
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from heparinized peripheral blood were recovered from healthy
adult donors (from the first affiliated hospital of Nanjing
Medical University) by Ficoll-Hypaque density gradient centri-
fugation.
Generation of McAb
Monoclonal antibodies were produced as follows. 6–8 week old
female BALB/c mice were intraperitoneally immunized with
1610
6 SPC-A1 cells three times over a 3–4 week interval, then
spleen cells were hybridized with SP2/0 (BALB/c mice myeloma
cell line) in 50% PEG-4000 (Sigma, USA) grown in HAT
medium in RPMI1640 (GIBCO, USA). Culture supernatants
were screened for antibody reactivity to WI-38 and SPC-A1 cells
using a live cell, solid- phase ELISA. Target cells (1610
5)w e r e
Figure 4. Inhibition of colony formation of SPC-A1 cells by
NJ001 in soft agar. (6100). The cell suspensions (2610
4 cells) mixed
with 0.3% agarose and different concentrations of NJ001 or MCA2849
were layered on the top of culture media in 6-well culture plates and
allowed to grow for 2 weeks before colonies were counted.
Representative contrast images were shown. (A) 0 mg/mL NJ001, (B)
100 mg/mL NJ001, (C) 200 mg/mL NJ001, (D) 400 mg/mL NJ001, (E) 0 mg/
mL MCA2849, (F) 100 mg/mL MCA2849, (G) 200 mg/mL MCA2849, (H)
400 mg/mL MCA2849.
doi:10.1371/journal.pone.0033009.g004
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5% CO2. The growth medium was then aspirated and the cells
were fixed for 15 min at room temperature with 95% ethanol.
The cell membranes were broken in triton X-100 for 20 min and
the cells were then blocked with 5% BSA for 60 min at room
temperature.
The positive hybridoma cells were subcloned using a limiting
dilution. Monoclonal hybridoma cells with a high valence against
SPC-A1 cells were expanded and retransfused into the abdominal
cavity of the BALB/c mice to prepare the ascites. The McAbs
were further purified from the ascites via Protein A affinity
chromatography.
The positive hybridoma cell were treated with colchicine. After
10% Giemsa dyeing, we observed mid-term nuclear cells and
analyzed the karyotype by the microscope.
Characterization of McAbs
The heavy and light chain composition of 3 McAbs were
determined using the ISO Strip Kit (Santa Cruz Biotechnology,
Inc, USA).
The extent of McAbs binding to various normal and malignant
cells (listed in Figure 1B) were determined with 0.1 mL of culture
supernatant from positive hybridoma cells and 1610
5 target cells
using ELISA for the screening described above, and the
production of substrate was measured spectrophotometrically at
450 nm.
Indirect Immunofluorescence Analysis
Indirect immunofluorescence was performed as follows. Briefly,
cells were grown to 80% confluence on cover slips and then fixed
in 95% ethanol at room temperature. After washing with PBS, the
cell membranes were broken in triton X-100 for 20 min and
blocked with 5% BSA for 60 min at room temperature, and then
incubated with purified NJ001 (1:80) at 37uC for 1 h. This was
followed by incubation with FITC conjugated goat-anti-mouse
IgG (1:100) for 45 min at room temperature. The slides were
counterstained with Hoechest. Immunofluorescence staining
results were obtained using fluorescence and confocal microscopy
(Zeiss LSM 710, Germany).
Western Blot Analysis
In order to perform the Western blot analysis, the nine cell lines
were initially cracked by the RIPA lysis buffer (50 mM Tris-HCl,
1% NP-40, 0.25% Na-deoxycholate, 50 mM NaCl, 1 mM EDTA,
1 mM PMSF, 1 mg/mL Aprotinin, 1 mM Na3VO4, 1 mM NaF).
Next, 25 mg of total protein from the nine cell lines was
electrophoresed on a 12% SDS-PAGE gel, and then transferred
to a PVDF membrane (Amersham Pharmacia Life Science, USA).
After blocking with 10% non-fat milk in TBST, the PVDF
membrane was incubated with NJ001 (1:300) and a anti-GAPDH
antibody (Zhongshan Biological, Beijing, China) over night at 4uC
to confirm equivalent protein loading in each lane. This was
followed by incubation with HRP-conjugated goat-anti-mouse
IgG for 1 h at room temperature. The PVDF membrane was
further washed 3 times with TBST for 15 min each, and finally
developed with ECL (Amersham Life Science) on X-ray film.
Immunohistochemistry
NSCLC tissues (n=106), SCLC tissues (n=21), breast
carcinoma tissues (n=21), gastric cancer tissues (n=5), colon
cancer tissues (n=5), ovarian cancer tissues (n=5), liver cancer
tissues (n=5), pulmonary pseudotumor tissues (n=25) and
adjacent nontumourous lung tissues (n=8) were obtained from
the department of pathology in the first affiliated hospital of
Nanjing Medical University. NSCLC tissues included lung
adenocarcinoma tissues (n=58) and squamous lung cancer tissues
(n=48). Tissue sections were treated with 0.3% hydrogen
peroxidase for 5 min, followed by 30 min blocking with normal
goat serum at room temperature. NM001 (1:200) was applied to
the blocked sections and incubated overnight at 4uC. The sections
were incubated for 30 min at 37uC with HRP-labeled goat-anti-
mouse IgG antibody (1:2,000), and the positive signals were
visualized by development in diaminobenzidine tetrahydrochlor-
ide (DAB) solution. The sections were viewed under an Olympus
Ax-70 DMC Ie CCD camera connected to a PC monitor.
Cell Proliferation Assay
SPC-A1 cells were seeded in a 96-well plate at 5,000 cells per
well. Culture supernatants from positive hybridoma cells and SP2/
0 cells were added. During the final 16 h of the 24 h, 48 h, and
72 h incubation at 37uC, the cells were pulsed with 0.5 mCi/well
[
3H] thymidine. Proliferation assays were performed by liquid
scintillation counting of the harvested cells. Results of SPC-A1 cell
proliferation measurement were presented as the count per minute
(cpm).
Soft Agar Assay
Colony formation was analyzed by soft agar assay. using the
anchorage-dependent, lung adenocarcinoma cell line SPC-A1 as a
tumor cell model, according to the procedures of Hong KW [40].
Figure 5. Photomicrographs of H&E staining in the preliminary study (6200). Representative areas of tissue sections from inoculation sites
in NJ001 group (A) and the excised tumors in control group (B).
doi:10.1371/journal.pone.0033009.g005
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containing of 2 mL culture medium was initially solidified in a
6-well culture plate. Next, 2 mL of 0.3% agarose solution
containing 2610
4 cells with different concentrations of NJ001 or
MCA2849 (irrelevant McAb) (0, 100, 200, 400, 800, or 1000 mg/
mL) was layered on top. Each dose was tested in triplicate. After
incubation at 37uC with 5% CO2 atmosphere for 2 weeks, the
colonies that contained over 50 cells were counted under a
microscope. The colony formation efficiency and the inhibition
ratio of the colony were calculated as the following formulas:
colony formation efficiency=(average number of colonies/aver-
age number of cells added per well)6100%; inhibition ratio of
colony formation=(1- average number of colonies in NJ001 or
MCA2849 group/average number of colonies in McAb free
group)6100%. This experiment was repeated 3 times.
Anti-tetanus McAb (MCA2849) (AbD Serotec, Germany) was
used as irrelevant McAb in this study.
Xenograft Experiment
Thirty female BALB/c nude mice of 6-week old were purchased
from Shanghai SLAC Laboratory Animal Co. Ltd. (Shanghai,
China). The SPC-A1 cells were maintained in 10% FBS
RPMI1640 medium until the cells reached 80% confluence. All
procedures were conducted in accordance to the Animal Care and
Use Committee guidelines of Nanjing Medical University.
In the preliminary study, SPC-A1 cells were incubated with
NJ001 at 37uC in a 5% CO2 incubator for 2 h. Thus each 200 mL
saline contained 2610
6 SPC-A1 cells and 400 mg NJ001. The
lateral axilla of 5 nude mice were inoculated subcutaneously with
the solution, and the control group, also composed of 5 mice, was
injected the equivalent SPC-A1 cells in the same position. After
three weeks of inoculation, mice were euthanized and the tissues
were obtained for H&E staining.
The mice were randomly divided into 4 groups, with 5 mice
per group. The xenograft was established by subcutaneous
injection of 2610
6 SPC-A1 cells/200 mL per mouse into the
lateral axilla. Antibodies were administered intraperitoneally at 3
different doses (200 mg, 400 mg, or 800 mg per mouse). Treatment
was initiated simultaneously with the implantation and consisted
of two steps: daily injection for the first week, followed by
injections twice a week for the proceeding two weeks. The control
group received sterile saline injections in the same mode. Animals
were monitored for tumor size at 4-day intervals. The tumor
volume (mm
3) was calculated according to the following equation:
Volume=width
26length/2 [28,41]. All mice were euthanized
three weeks after the initiation of treatment and tumors were
removed and weighed. Tumor growth inhibition was calculated
by the formula: tumor growth inhibition ratio=(12average
tumor weight in NJ001 group/average tumor weight in control
group)6100%. Treatment toxicity was assessed by the physical
appearance of the animals.
H&E Staining
Tissues obtained were fixed in 10% formalin and embedded in
paraffin. The embedded tissues were subsequently cut into 4 mm
sections and placed on glass slides for H&E staining.
Apoptosis Assay
SPC-A1 cells were seeded in a 12-well plate at 1610
5 cells per
well. After overnight incubation, SPC-A1 cells were cultured
with or without 200 mg/mL NJ001 or MCA2849 for 24 h and
48 h. Each time point was tested in triplicate. The morpholog-
ical changes of the cells were then observed and the rate of
apoptosis was determined by flow cytometry. Briefly, cells were
collected, washed with PBS and resuspended in 500 mLb i n d i n g
buffer containing 10 mmol/L HEPES-NaOH (pH 7.4),
140 mmol/L NaCl, and 2.5 mmol/L CaCl2.N e x t ,5 mLo f
Annexin V-FITC (Bender MedSystems, Austria) and 5 mLo f
propidium iodide (PI) solution (Bender) were added and the cells
were then incubated in the dark for 15 min. The fluorescence
was then analyzed by flow cytometry. Early apoptosis and late
apoptosis was determined as the percentage of Annexin V
+/PI
2
cells and Annexin V
+/PI
+ cells, respectively. The rate of total
apoptosis was the sum of early and late apoptosis. This
experiment was repeated 3 times.
Statistical Analysis
All values were expressed as mean 6 standard deviation. Mean
comparison of groups was conducted using single factor variance
analysis. The pairwise comparison was performed with the LSD
test if the variance was homogeneous and a P-value,0.05 was
regarded as statistically significant, while Dunnett’s C method was
used for the heterogeneity of variance, setting 0.05 as the
significance level.
Figure 6. Inhibition of tumor growth in vivo by NJ001 in the
SPC-A1 xenograft model. (A) Tumor growth curve. Animals were
subcutaneously injected with 2610
6 SPC-A1 cells and intraperitoneally
injected with normal saline, 200 mg, 400 mg, or 800 mg NJ001. Tumor
volumes were measured at 4-day intervals. The error bars represent
standard deviation. (B) Average tumor weight in the antibody and
control groups. After 3 weeks of treatment, tumors were excised and
weighed. The error bars represent standard deviation. * P,0.05
compared to the control group. ‘ P,0.05 compared to the 200 mg
NJ001 group.
doi:10.1371/journal.pone.0033009.g006
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mean 6 SD of three independent experiments (**P,0.001). The amount of late apoptosis was determined as the percentage of Annexin V
+/PI
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